Every Form 4 that Apimeds Pharmaceuticals US, Inc. (APUS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APUS filings page.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an amended Form 4 to correct how an insider’s holdings are reported. The filing shows that 4,316,618 shares of common stock are held indirectly through Apimeds Inc. (“Apimeds Korea”), a wholly owned subsidiary of the reporting person.
The amendment explains that earlier filings incorrectly showed a Convertible Promissory Note of $184,833 and the related common shares as indirectly owned through Apimeds Korea. As of May 12, 2025, the reporting person had direct beneficial ownership of 2,099,747 common shares and indirect beneficial ownership of 4,316,618 common shares held by Apimeds Korea. The insider also disclaims beneficial ownership of the subsidiary-held shares for certain legal purposes.
Apimeds Pharmaceuticals US, Inc. (APUS) — Form 4 insider activity: A director reported the grant of a stock option for 10,000 shares with an exercise price of $2.67 per share on 11/11/2025. The option expires on 11/11/2035 and was reported as directly owned.
The award vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. The option is not exercisable until stockholder approval is obtained to amend the company’s incentive plan to increase available shares. The award will vest in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s stock option grant. On 11/11/2025, the reporting person received an option to buy 10,000 shares of common stock at an exercise price of $2.67 per share, expiring on 11/11/2035. The award was coded as an acquisition and priced at $0 for the derivative grant, with 10,000 derivative securities beneficially owned directly after the transaction.
The option vests in quarterly installments beginning October 1, 2025 over three years and becomes exercisable only after stockholder approval of an amendment to increase shares available under the incentive plan. It vests in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a Form 4 for a director showing a grant of a stock option for 10,000 shares at an exercise price of $2.67 on 11/11/2025.
The option expires on 11/11/2035 and vests quarterly beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval of an amendment to the incentive plan to increase available shares. The option vests in full upon a Change in Control.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a routine insider equity grant. A director received a stock option covering 10,000 shares on 11/11/2025 with an exercise price of $2.67 and an expiration date of 11/11/2035.
The option vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval is obtained for an amendment to the company’s incentive plan to increase shares available under the plan. The award vests in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) disclosed a director stock option grant. On 11/11/2025, the reporting person acquired a stock option for 10,000 shares at an exercise price of $2.67, with an expiration date of 11/11/2035. The option was received for $0 and is held as Direct (D) ownership.
The award vests in quarterly installments beginning October 1, 2025 and will be fully vested after three years, subject to continued service on each vesting date. It is not exercisable until stockholder approval is obtained for an amendment to the Company’s incentive plan to increase available shares. The option will vest in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) director reported receiving a stock option grant. The option covers 3,000 shares of common stock at an exercise price of $1.92 per share, granted on 10/15/2025 and expiring on 10/15/2035.
The award vests in quarterly installments beginning October 1, 2025 and becomes fully vested after three years, subject to continued service. It is not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares. The option vests in full upon a Change in Control as defined in the plan.
Following the transaction, the reporting person beneficially owns 3,000 derivative securities on a direct basis.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director stock option grant on a Form 4. The award covers 3,000 stock options at an exercise price of $1.92, granted on October 15, 2025, and expiring on October 15, 2035. Vesting occurs quarterly beginning October 1, 2025 and completes after three years, contingent on continued service. The option is not exercisable until stockholders approve an amendment to increase shares under the incentive plan; it vests in full upon a Change in Control.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s stock option grant on a Form 4. The award covers 3,000 stock options at an exercise price of $1.92, granted on 10/15/2025 and expiring on 10/15/2035.
The options vest in quarterly installments beginning October 1, 2025, becoming fully vested after three years, subject to continued service on each vesting date. The options are not exercisable until stockholder approval is obtained to amend the company’s incentive plan to increase shares available. The award will vest in full upon a Change in Control as defined in the plan. Following the transaction, the reporting person holds 3,000 derivative securities with direct ownership.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s grant of stock options. The filing shows 3,000 options at an exercise price of $1.92 per share on 10/15/2025, owned directly.
The options vest in quarterly installments beginning October 1, 2025 and become fully vested after three years. They are not exercisable until stockholder approval of an amendment to increase shares under the company’s incentive plan. The award accelerates to full vesting upon a Change in Control and expires on 10/15/2035.
Apimeds Pharmaceuticals US, Inc. (APUS) insider filing: A director and officer (Chairman and CMO) reported a grant of 3,000 stock options on 10/15/2025 at an exercise price of $1.92 per share. The options expire on 10/15/2035 and vest in quarterly installments beginning October 1, 2025, becoming fully vested after three years, contingent on continued service. The options are not exercisable until stockholders approve an amendment to increase shares under the incentive plan. Following the grant, 3,000 derivative securities are beneficially owned directly.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s grant of stock options. The filing shows 3,000 stock options acquired on 10/15/2025 at an exercise price of $1.92 per share, expiring on 10/15/2035. Following the transaction, the reporting person beneficially owns 3,000 derivative securities, held directly.
The options vest in quarterly installments beginning October 1, 2025 and become fully vested after three years, with full vesting upon a Change in Control as defined in the plan. The options are not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a routine insider equity grant. The company’s Chief Executive Officer and Director received a stock option to purchase 215,000 shares at an exercise price of $1.92 on 10/15/2025. The option vests in quarterly installments beginning October 1, 2025 and is fully vested after three years, with full vesting upon a Change in Control. It is not exercisable until stockholders approve an amendment to the incentive plan to increase available shares. The option expires on 10/15/2035.